The price of Biocept, Inc. (NASDAQ:BIOC) over the past year has decreased -10.57% while the S&P 500 has increased 18.74%. During the past 20 days, BIOC has decreased -10.47% while the broad market has increased 1.77%. BIOC ‘s 20-day moving average currently sits above its 100-day moving average. This is a bullish signal that suggests the stock price might continue to rise. BIOC’s average trading volume during the past 20 days is lower than the average volume over the past 100 days, which could be an indication that investors are feeling less certain than usual about the direction of BIOC’s future price movements.
Recent trading patterns in the stock of Biocept, Inc. (BIOC) have investors on high alert. The idea that stock performance can best be predicted by analyzing past trading data is a widely held view among financial professionals. In the case of BIOC, the data could have some interesting implications for future performance. In the most recent quarter, institutional ownership increased by a net of 305453 shares, or 12.73%.This is a bullish sign and indicates that institutions are feeling more optimistic about the outlook for BIOC overall.10 holders increased their positions, 6 decreased their positions, and 7 holders held their positions.
Among institutions that increased their positions, 4 were new positions. Among holders that decreased their positions, 1 sold out of the stock Biocept, Inc.. Insider ownership during the latest quarter decreased by a net of 0 shares, indicating that BIOC’s key executives are feeling more bearish about the stock than they did three months ago. Insider ownership during the last year has decreased by a net of 1.56 million shares. 57.14% of insider trades in the last 12 months were buys, and 42.86% were sells.
Biocept, Inc. (NASDAQ:BIOC) has a 20-day RSI of 46.90%. According to this momentum indicator, a reading between 30 and 70 suggests the stock is not especially cheap or expensive, and not on the brink of a trend reversal. The MACD tells a different story. BIOC’s 9-day MACD currently sits below the 20-day MACD, indicating that BIOC’s upside momentum has decreased during the last three weeks. This suggests that the trend might soon reverse. BIOC’s average trading volatility during the past few weeks is 94.61% higher than the average volatility over the past 100 days. This means that the stock’s daily price swings have been more extreme in recent times compared to the past.
Analysts expect Biocept, Inc. (BIOC) to generate earnings per share of $0.76 in 2017. This works out to a decrease of -60.42% compared to last year’s earnings. For comparison’s sake, analysts expect the S&P 500 to grow earnings by an average of 12% in 2017. The average investment rating for BIOC on a scale of 1 to 5 (1 being a strong sell and 5 being a strong buy) is a 5.00 or a Strong Buy. Three months ago, analysts assigned BIOC a 5.00 rating, which implies that analysts largely still feel the same about the outlook for the stock over the next year.